Seasonal Variation in Flares of Inflammatory Bowel Disease in a Korean Population

Jae Hyun Jang; Su Hee Lee; Jun Mo Sung; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Il Park
April 2012
Intestinal Research;2012, Vol. 10 Issue 2, p161
Academic Journal
Background/Aims: Conflicting data have been reported about the seasonal variation in flare-up of inflammatory bowel disease (IBD). The aim of this study was to assess the occurrence of seasonal variations in flare-up of IBD in the Korean population. Methods: Patients with IBD, who underwent more than 1 year of follow-up and showed more than 1 episode of flare-up, were included. Flares of disease were refined as follows; receipt of a new prescription and increasing dose of corticosteroids, 5-ASA or immunosuppressant; hospitalized or operated due to development and worsening of symptoms; elevation of inflammatory marker due to worsening of Crohn's Disease Activity Index (CDAI) or Mayo score. In addition, for patients with more than two episodes of flare-up, they were investigated in a monthly and seasonal pattern. Results: Of 573 patients with IBD, 46 patients with Crohn's disease and 61 patients with ulcerative colitis were enrolled. There was no association between month of the year and flare of Crohn's disease (P=0.06) or ulcerative colitis (P=0.58). Further, no association between season of the year and flare of Crohn's disease (P=0.06) or ulcerative colitis (P=0.68). However, in Crohn's disease who experience 2 or more flare-ups, symptoms occurred more frequently during winter, especially December (P=0.029). Conclusions: In the Korean population, there was no association of seasonal and monthly variation in flares of Crohn's disease and ulcerative colitis. However, in Crohn's disease, individuals with 2 flar-up or more, symptoms occurred more frequently during December.


Related Articles

  • Cytokine and Anti-cytokine Therapies for Inflammatory Bowel Disease. Ogata, Haruhiko; Hibi, Toshifumi // Current Pharmaceutical Design;May2003, Vol. 9 Issue 14, p1107 

    Although the pathogenesis of inflammatory bowel disease (IBD) remains elusive, it appears that there is chronic activation of the immune and inflammatory cascade in genetically susceptible individuals. Current disease management guidelines have therefore focused on the use of anti-inflammatory...

  • Corticosteroids.  // Reactions Weekly;1/12/2008, Issue 1184, p14 

    The article describes the case of four patients with inflammatory bowel disease and who developed steroid allergy during treatment with corticosteroids. Three patients, a 40-year old man with Crohn's disease, a 53-year old woman and a 39-year old man both with ulcerative colitis, developed...

  • Budesonide: Teaching an Old Dog New Tricks for Inflammatory Bowel Disease Treatment. Angelucci, Erika; Malesci, Alberto; Danese, Silvio // Current Medicinal Chemistry;2008, Vol. 15 Issue 24, p2527 

    Crohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative...

  • Where the Rubber Meets the Road. WEINER, GARY // Naturopathic Doctor News & Review;Jan2014, Vol. 10 Issue 1, p1 

    The article focuses on treatment of inflammatory bowel disease (IBD), one of the five most prevalent gastrointestinal diseases in the U.S. IBD is comprised of ulcerative colitis (UC) and Crohn's disease (CD). It states that IBD is without a medical cure and often requires a lifetime of care. The...

  • Nutritional status and nutritional therapy in inflammatory bowel diseases. Hartman, Corina; Eliakim, Rami; Shamir, Raanan; Koutroubakis, Ioannis E. // World Journal of Gastroenterology;6/7/2009, Vol. 15 Issue 21, p2570 

    Underweight and specific nutrient deficiencies are frequent in adult patients with inflammatory bowel disease (IBD). In addition, a significant number of children with IBD, especially Crohn's disease (CD) have impaired linear growth. Nutrition has an important role in the management of IBD. In...

  • Profile of soluble cytokine receptors in Crohn's disease. Gustot, T.; Lemmers, A.; Louis, E.; Nicaise, C.; Quertinmont, E.; Belaiche, J.; Roland, S.; Van Gossum, A.; Devière, J.; Franchimont, D. // Gut;Apr2005, Vol. 54 Issue 4, p488 

    Introduction: Soluble cytokine receptors (sCRs) modulate the in vivo activity of cytokines. Deficient sCR production could participate in the pathogenesis and course of Crohn's disease (CD). The aim of the study was to examine the profile of sCRs in CD patients and their modulation by infliximab...

  • Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p78 

    This excellent review summarizes the current challenges in IBD clinical trials and gives a rational series of recommendations for improvements.

  • Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease. Argüelles-Arias, F.; Castro-Laria, L.; Lobatón, T.; Aguas-Peris, M.; Rojas-Feria, M.; Barreiro-de Acosta, M.; Soto-Escribano, P.; Calvo-Moya, M.; Ginard-Vicens, D.; Chaparro-Sánchez, M.; Hernández-Durán, M.; Castro-Senosiain, B.; Fernández-Villaverde, A.; García-Sánchez, V.; Domínguez-Muñoz, E.; Caunedo-Álvarez, A.; Herrerías-Gutiérrez, J. // Digestive Diseases & Sciences;Oct2013, Vol. 58 Issue 10, p2949 

    Background: Pyoderma gangrenosum is a serious cutaneous complication seen in approximately 1 % of patients with inflammatory bowel disease (IBD). Oral corticosteroids are the mainstay treatment, although the evidence supporting their use is weak. Aims: The purpose of this study was to...

  • 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Van Staa, T. P.; Card, T.; Logan, R. F.; Leufkens, H. G. M. // Gut;Nov2005, Vol. 54 Issue 11, p1573 

    Background and aims: The objective of this study was to evaluate the risk of colorectal cancer (CRC) in patients taking aminosalicylates (5-ASA) for inflammatory bowel disease (IBD). Methods: The General Practice Research Database (GPRD) which contains the primary care records of five million...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics